Fund Holdings — CAXTON CORP

Total Portfolio Value:
$19.73M
Total Bought:
$494.0K
Total Sold:
$42.3K
Net Transaction:
+$451.7K
Securities
▲▼
SharesValue
Q1 2024
▲▼
Q2 2024
▲▼
Change
▲▼
Q1 2024
▲▼
Q2 2024
▲▼
Weight (%)
▲▼
Change
▲▼
Xeris Biopharma Holdings Inc5,113,3485,113,3480$11.30M$11.51M58.31%+$204.5K
Rezolute, Inc.(RZLT)1,318,9671,318,9670$3.36M$5.67M28.74%+$2.31M
State Street SPDR S&P 500 ETF TrustTR UNIT(SPY)1,8561,869+13$971.0K$1.02M5.15%+$45.9K
Berkshire Hathaway Inc DelCL B1,0191,025+6$428.3K$417.1K2.11%-$11.2K
Lexeo Therapeutics, Inc.(LXEO)10,31917,851+7,532$161.8K$286.3K1.45%+$124.5K
Mind Medicine Inc29,06530,383+1,318$273.2K$219.1K1.11%-$54.1K
ABIVAX Société AnonymeADS(ABVX)15,80813,900-1,908$226.1K$183.8K0.93%-$42.3K
Kyverna Therapeutics, Inc.(KYTX)15,84622,981+7,135$393.6K$172.4K0.87%-$221.3K
Molecular Templates Inc136,866136,8660$306.6K$157.4K0.80%-$149.2K
Compass Therapeutics, Inc.(CMPX)43,46543,4650$86.1K$43.5K0.22%-$42.6K
Context Therapeutics Inc.(CNTX)018,403+18,403$0$36.9K0.19%+$36.9K
Adicet Bio Inc17,48817,4880$41.1K$21.2K0.11%-$19.9K
Page 1 of 1
CAXTON CORP — 13F Holdings — Q2 2024 | TickerTrail